Marinus Pharma (MRNS) Misses Q2 EPS by 4c ; Offers Guidance

Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.63), $0.04 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $8.06 million versus the consensus estimate of $9.5 million.

GUIDANCE:

Marinus Pharma sees FY2024 revenue of $33-35 million, versus the consensus of $39.35 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Micron Technology (MU) call put ratio 1 calls to 1 put into quarter results
• Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink